The Community Guide

- gsearch

Search Results

Narrow Results:

2018 2
2013 1

Journal Article 3

1 - 3 of 3 Results

Refine Results

Refine Results:

Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target

CITE Title : Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target Personal Author(s) : Jung, Jae Hun;You, Sungyong;Oh, Jae Won;Yoon, Junhee;Yeon, Austin;Shahid, Muhammad;Cho, Eunho;Sairam, Vikram;Park, Taeeun D.;Kim, Kwang Pyo;Kim, Jayoung; Published Date : August 24 2018;11-28-; Source : Cancer Lett. 437:1-12 URL : https://stacks.cdc.gov/view/cdc/59722 Jung, Jae Hun et al. (2018). Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. 437 Jung, Jae Hun et al. "Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target" 437 (2018) Jung, Jae Hun et al. "Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target" vol. 437, 2018 Export RIS Citation Information.

:

Jung, Jae Hun ;

You, Sungyong

August 24 2018 | Cancer Lett. 437:1-12

:

Background:Cisplatin-based chemotherapy is currently part of the standard of care for bladder cancer (BC). Unfortunately, some patients respond poorly...
Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance

CITE Title : Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance Personal Author(s) : Lee, Min Young;Yeon, Austin;Shahid, Muhammad;Cho, Eunho;Sairam, Vikram;Figlin, Robert;Kim, Khae-Hwan;Kim, Jayoung; Published Date : Jan 13 2018 Source : Oncotarget. 2018; 9(17):13231-13243. URL : https://stacks.cdc.gov/view/cdc/53728 Lee, Min Young et al. (2018). Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance. 9(17). Lee, Min Young et al. "Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance" 9, no. 17 (2018) Lee, Min Young et al. "Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance" vol. 9, no. 17, 2018 Export RIS Citation Information.

:

Lee, Min Young ;

Yeon, Austin

Jan 13 2018 | Oncotarget. 2018; 9(17):13231-13243.

:

Due to its tendency to recur and acquire chemoresistance quickly, bladder cancer (BC) remains to be an elusive and difficult disease. Patients with re...
Body mass and smoking are modifiable risk factors for recurrent bladder cancer

CITE Title : Body mass and smoking are modifiable risk factors for recurrent bladder cancer Personal Author(s) : Wyszynski, Asaf;Tanyos, Sam A.;Rees, Judy R.;Marsit, Carmen J.;Kelsey, Karl T.;Schned, Alan R.;Pendleton, Eben M.;Celaya, Maria O.;Zens, Michael S.;Karagas, Margaret R.;Andrew, Angeline S.; Published Date : Oct 10 2013 Source : Cancer. 120(3):408-414. URL : https://stacks.cdc.gov/view/cdc/29875 Wyszynski, Asaf et al. (2013). Body mass and smoking are modifiable risk factors for recurrent bladder cancer. 120(3). Wyszynski, Asaf et al. "Body mass and smoking are modifiable risk factors for recurrent bladder cancer" 120, no. 3 (2013) Wyszynski, Asaf et al. "Body mass and smoking are modifiable risk factors for recurrent bladder cancer" vol. 120, no. 3, 2013 Export RIS Citation Information.

:

Wyszynski, Asaf ;

Tanyos, Sam A.

Oct 10 2013 | Cancer. 120(3):408-414.

:

BackgroundIn the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women. Recurrences frequently occ...